Glass based biomaterials are proposed as biomaterials for a number of biomedical applications such as dental, maxillofacial and orthopaedic bone substitutes; bone tissue engineering scaffolds; and antimicrobial ion delivery vehicles. They are either silicate or phosphate based. Degradation of such glasses in the biological environment can be controlled very effectively by changing the initial chemical composition. And from a biological perspective, the components of bioactive glass (are part of bone tissue and) does not give an adverse reaction from the host tissue. The released products are ionic components of glass which govern the bioactivity of the bio-environment by influencing cell proliferation and tissue regeneration. Additional functionalities such antimicrobial, anti-inflammatory and angiogenic effects can also be incorporated in the glass. One of our target application is in dentistry for which the glass product will be used as alloplastic material as bone filler material.
Bone is the second most common transplantation tissue after blood. Bone grafting is the widely applied and universally accepted technique in several types of surgeries, such as orthopedic surgery, plastic surgery, oral and maxillofacial surgery and dental surgery. At present, bone restoration therapies generally involve transplantation of bone tissue from healthy parts of the same patient (autograft) or from a donor of human origin (allograft) or animal origin (xenograft). The use of autograft is limited due to less availability and potentially complicated harvesting procedure. Allografts and Xenografts have more limitations in the essential bone graft characteristics which yields more variable clinical results. In addition, they carry the risk of transferring viral diseases. The processing of tissue lowers this risk but, that can significantly weaken the biologic and mechanical properties initially present in the bone tissue.
Due to the problems associated with substitute bone grafts from biological origin, a variety of synthetic materials ranging from hydroxyapatites and related calcium phosphate materials to silicate-based bioactive glasses including Bioglass® have been developed and commercialized. In clinical studies, silicate-based glasses have been shown to provide improved performance over hydroxyapatite for the treatment of bone defects. Phosphate glasses in turn possess several potential advantages over silicate glasses such as greater control over the glass degradation properties, improved toxicity characteristics due to absence of silica, and easier processability.
SynThera biomedical will exploit its core competency in glass manufacturing and processing for bone graft applications. The glass in the form of particles (regular or irregular shape) with precise size, Putty (for easy handling of large defects) and in the form of scaffolds (for lager defects) will be manufactured.